Expert Panel - Pediatric Bone Marrow Failure - 2025 San Francisco Bay Area Conference
The Pediatric Hematology/Oncology Experts answer questions from the audience at the 2025 San Francisco Bay Area Patient and Family Conference.
treatment
Transitioning to Adult Care - 2025 San Francisco Bay Area Patient and Family Conference
Pediatric MDS - Session from the 2025 San Francisco Bay Area Patient and Family Conference
Pediatric PNH - from the 2025 San Francisco Bay Area Patient and Family Conference
Pediatric Aplastic Anemia - 2025 San Francisco Patient and Family Conference
23-Year Aplastic Anemia Survivor Speaks - 2025 San Francisco Bay Area Patient/Family Conference
CureAA: Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia
Clinical Trial If you are interested in learning more about your possible participation in this clinical trial, please complete the form. Your information will be forwarded directly to the trial sponsor.
Find Out More:
Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD–mutated AML
Abstract
Iptacopan Yields Meaningful Hemoglobin Improvements in Pretreated PNH Group
Low rates of chronic graft-versus-host disease with ruxolitinib maintenance following allogeneic HCT
Key Points
Prolonged ruxolitinib administration after allogeneic HCT is associated with low rates of clinically significant chronic GVHD.